Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The D-alanyl-D-alanine (D-Ala-D-Ala) terminus is a critical structural motif found in the peptidoglycan precursors of Gram-positive bacteria, specifically within Lipid II and the pentapeptide chain (NCBI, NBK459359). It serves as the substrate for transpeptidase enzymes, also known as penicillin-binding proteins, which cross-link the peptidoglycan layers to provide mechanical strength to the bacterial cell wall (PubMed, 16119961). This terminus is the primary molecular target for glycopeptide antibiotics, such as vancomycin and teicoplanin, which bind to the D-Ala-D-Ala dipeptide through a network of hydrogen bonds (StatPearls, NBK459359). By sequestering this motif, these drugs sterically hinder the enzymatic reactions required for cell wall assembly, leading to bacterial cell lysis and death (PubChem, CID 14969). Resistance to these antibiotics often arises through the modification of this terminus to D-alanyl-D-lactate (D-Ala-D-Lac), which significantly reduces the binding affinity of the drugs (PubMed, 10640681). Understanding this target is essential for treating serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and other multidrug-resistant Gram-positive pathogens. The specificity of glycopeptides for this bacterial-specific motif minimizes direct interference with human cellular processes, although secondary toxicities can occur. Newer lipoglycopeptides like dalbavancin and oritavancin also target this site but include additional mechanisms to enhance potency and overcome certain resistance phenotypes.
Glycopeptide antibiotics bind to the D-Ala-D-Ala terminus via five hydrogen bonds, sterically inhibiting the transglycosylation and transpeptidation steps of peptidoglycan synthesis (StatPearls, NBK459359).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on D-alanyl-D-alanine terminus of peptidoglycan precursors (D-Ala-D-Ala) (D-Ala-D-Ala).